Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease (Q24186291)

22 October 2023

Petrease H Patton

2

Petrease H

Patton

1 reference

22 October 2023

David J Tsoulis

3

David J

Tsoulis

1 reference

22 October 2023

Benson S Thomas

4

Benson S

Thomas

1 reference

22 October 2023

John K MacDonald

5

John K

MacDonald

1 reference

Cochrane Database of Systematic Reviews

22 October 2023

language of work or name

1 reference

30 October 2015

0 references

published in

0 references

cites work

A controlled double blind study of azathioprine in the management of Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

A controlled trial of azathioprine in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

Effect of azathioprine or mesalazine therapy on incidence of re-hospitalization in sub-occlusive ileocecal Crohn's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

Controlled trial of azathioprine in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

Methotrexate for maintenance of remission in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

Clinical pharmacology and pharmacogenetics of thiopurines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

Azathioprine for maintaining remission of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

Therapy of Metronidazole With Azathioprine to Prevent Postoperative Recurrence of Crohn's Disease: A Controlled Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

7 January 2021

Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

7 January 2021

The long-term efficacy of azathioprine does not wane after four years of continuous treatment in patients with steroid-dependent luminal Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

7 January 2021

Azathioprine in Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

7 January 2021

Controlled trial of azathioprine in Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

7 January 2021

A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

7 January 2021

Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

7 January 2021

Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

7 January 2021

6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

7 January 2021

Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following year

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

7 January 2021

Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

7 January 2021

Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000067.PUB3

7 January 2021